![]() |
市场调查报告书
商品编码
1467654
2024-2032 年血管内动脉瘤修復市场报告(按适应症(腹主动脉瘤、胸主动脉瘤、胸腹主动脉瘤等)、产品、性别、年龄、最终用户和地区)Endovascular Aneurysm Repair Market Report by Indication (Abdominal Aortic Aneurysm, Thoracic Aortic Aneurysm, Thoracoabdominal Aortic Aneurysm, and Others), Product, Gender, Age, End-User, and Region 2024-2032 |
IMARC Group年,全球血管内动脉瘤修復(EVAR)市场规模达30亿美元。 。
动脉瘤是指动脉壁因衰弱或变性而增大。它通常与烟草消费和吸烟有关。在患有动脉粥状硬化、高胆固醇和结缔组织疾病等疾病的族群中,动脉瘤的盛行率也较高。血管内动脉瘤修復(EVAR)是指修復这些动脉瘤的微创手术。 EVAR 手术是透过将覆盖支架(带有一层织物的金属网管)插入动脉的薄弱区域来进行的。这为血液流动提供了一条通道,而不会积聚在凸起处,并防止其破裂。如今,市面上有多种用于治疗动脉瘤的设备。
EVAR治疗比传统手术相对安全,因为不需要进行手术。因此,该技术可以缩短住院时间并加快康復速度。由于动脉瘤的盛行率以及老年人口的不断增长,医疗保健提供者越来越多地采用血管内治疗。人们对该手术潜在益处的认识不断提高,进一步支持了这一点。此外,全球各国政府正在实施多项计划,以改善成本结构并提高患者对 EVAR 设备和治疗程序可用性的认识。为此,医疗机构正在开发 EVAR 设备和技术,以提供更快的恢復和更少的併发症。例如,已经创建了增强的移植技术,可以实现短着陆区的治疗并提高对动脉曲率的顺应性。这些技术进一步帮助提高了 EVAR 手术的成功率。
The global endovascular aneurysm repair (EVAR) market size reached US$ 3.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 4.3 Billion by 2032, exhibiting a growth rate (CAGR) of 4.1% during 2024-2032.
An aneurysm refers to the enlargement of the arterial wall due to weakness or degeneration. It is generally associated with tobacco consumption and smoking. The prevalence of aneurysms is also higher among people with medical conditions such as atherosclerosis, high cholesterol levels, and connective tissue disorder. Endovascular aneurysm repair (EVAR) refers to a minimally invasive procedure or surgery that is performed to repair these aneurysms. EVAR procedure is performed by inserting a covered stent, a metal mesh tube with a layer of fabric, into the weak area of the artery. This provides a route for the blood to flow without accumulating in the bulge and prevents it from bursting. Nowadays, multiple devices are available in the market that are used to treat aneurysms.
The EVAR treatment is comparatively safer than traditional procedures, as there is no need for performing surgery. As a result, this technique results in short hospital stays and quicker recovery. Due to the prevalence of aneurysms, along with the growing geriatric population, endovascular treatment is increasingly being adopted by healthcare providers. This has further been supported by the rising awareness of the potential benefits of the procedure. Also, governments across the globe are undertaking several programs to improve the cost structure and spread awareness about the availability of EVAR devices and treatment procedures among patients. In line with this, healthcare institutions are developing EVAR devices and technologies that offer faster recovery and fewer complications. For instance, enhanced graft technologies have been created, which allow treatments with short landing zones and improve conformability to the artery curvature. These technologies have further helped in increasing the success rate of EVAR procedures.
IMARC Group provides an analysis of the key trends in each sub-segment of the global endovascular aneurysm repair (EVAR) market report, along with forecasts at the global and regional level from 2024-2032. Our report has categorized the market based on indication, product, gender, age and end-user.
Abdominal Aortic Aneurysm (AAA)
Thoracic Aortic Aneurysm (TAA)
Thoracoabdominal Aortic Aneurysm (TAAA)
Others
Percutaneous EVAR
Fenestrated EVAR
Aortic Stents and TAA Grafts
Others
Male
Female
Pediatric
Adult
Geriatric
Hospitals
Clinics
Ambulatory Surgical Centers
Others
Asia Pacific
Europe
North America
Middle East and Africa
Latin America
The report has also analyzed the competitive landscape of the market with some of the key players being Medtronic plc, Cook Group Incorporated, W. L. Gore & Associates, Inc., Bolton Medical, Inc., Gamida Cell Ltd., JOTEC GmbH, Getinge AB (Maquet), Shanghai MicroPort Medical (Group) Co., Ltd., Terumo Corporation, Endologix, Inc., Lombard Medical Limited, and Cardinal Health, Inc.